TAVR in Bicuspid Patients: Are Outcomes the Same in Men and Women?

Bicuspid aortic valve stenosis (BAV) has not yet been analyzed in large, randomized studies, and TAVR in this scenario has been assessed only by small fairly studies. However, the information available is quite promising.  

TAVI en bicúspides

TAVR in women generally presents more complications than in men, but severe bicuspid aortic valve stenosis receiving TAVR has not been well looked at. 

This study included 510 patients from one singe center. 225 women (44.1%) and 285 men.

The valve most used was Venus-A Valve (Venus Medtech).

Mean age was 72; men presented more comorbidities, such as kidney failure, COPD and prior heart disease and PCI, in addition to lower left ventricular ejection fraction and more aortic failure associated to stenosis. 

On the other hand, women presented higher aortic velocity and less ascending aortic dilation. 

STS was similar: 5.6±3.8% for women and 4.9±4.2 for men (P=0.066).

Read also: Aspiration Thrombectomy in Acute Coronary Syndrome: Is the Japanese Perspective a Strategy to Emulate?

CT showed type 0 BAV was the most frequent in women and Type I in men. The latter presented more calcification, with larger aortic annuli, valve area and aortic root size. 

During the procedure, the need for a second valve was greater in men. However, there were more vascular complications in women.  

At hospital level, there were no differences in mortality or stroke, neither in need for pacemaker implantation (women 17.1% vs. 22.5% p=0.1).

Read also: Balloon expandable vs Self-Expanding Valves: The Best Option for ViV-TAVR in Small Annuli.

At 30 days and one year, there were no differences in mortality.

Eco-Doppler were analyzed at 30 days and one year. Women presented higher gradient but fewer major to mild paravalvular leaks without reaching statistical value. Both groups improved ejection fraction and presented reduced ventricular mass.

At multivariable analysis, bleeding was a mortality predictor in women while creatinine level and aortic root diameter >45 mm were predictors in men.

Conclusion

In patients with bicuspid aortic valves receiving TAVR, women presented fewer comorbidities, while men more often presented type I BAV, more calcification and larger aortic roots. At hospital level, men presented better evolution, fewer complications but more need of a second valve. Survival at one year was similar between sexes. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: Sex Difference in Outcomes Following Transcatheter Aortic Valve Replacement in Bicuspid Aortic Stenosis.

Reference: Jing-Jing He, et al. J Am Coll Cardiol Intv 2022;15:1652–1660.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

TAVR in Young Low-Risk Patients

Transcatheter aortic valve replacement (TAVR) has established itself as an effective strategy for the treatment of severe aortic stenosis across different risk groups. While previous...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...